We're excited to advance toward these milestones and highlight tibulizumab's potential as a best-in-class therapy for these underserved diseases." In September 2024, the protocol for the Phase 2 ...

XBP Europe Holdings, Inc. (“XBP Europe” or “the Company”) (NASDAQ: XBP), a pan-European integrator of bills, payments, and related solutions and services seeking to enable the digital transformation ...